Shire Calling on Luck of the Irish with $32 Billion Baxalta Buy

Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--In a bold move to become a major player in the "orphan drug" or rare disease market, Irish drug maker Shire Plc (NASDAQ:SHPG) (Dublin, Ireland) is investing just over $32 billion to purchase Baxalta (NYSE:BXLTY) (Bannockburn, Illinois). In planning for over six months, Shire estimates the deal would form a company with potential sales near $20 billion in just four years.

Within this article: Details the new company's development programs supported by Balxalta's recently approved products. Other companies featured: Baxter International (NYSE:BAX)